Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.15
Bid: 4.00
Ask: 4.30
Change: 0.10 (2.47%)
Spread: 0.30 (7.50%)
Open: 4.05
High: 4.29
Low: 4.05
Prev. Close: 4.05
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cohort trading ahead of expectations, record orders

Tue, 26th Sep 2023 19:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cohort PLC - Reading, England-based defence and security technology firm - Updates on first quarter trading ahead of annual general meeting. Achieved record financial results in the year ended April 30, with strong performances in revenue and adjusted operating profit that exceeded market expectations. "We finished the year with a robust cash position and a record closing order book of GBP329.1 million stretching out to 2032, with strong revenue cover for the current financial year," firm adds. Explains following contract wins since the start of the financial year of over GBP90 million, the order book on September 22 stood at GBP370 million, representing consensus revenue cover for the current financial year of 93%. Retains significant cash and banking facilities to fund its currently anticipated commitments and, potentially, to finance future acquisitions. As a result of planned capital expenditure and expansion in working capital, anticipates net cash balance will decrease, but that it will maintain positive net funds at the year end. States expectations for the full year remain unchanged.

----------

Beowulf Mining PLC - Sweden, Finland and Kosovo-focused mining company -Updates on the development plans for the graphite anode materials plant in GigaVaasa. Plans to advance parallel environmental and technical work streams for the development of the GAMP. Says the environmental impact assessment is underway and is expected to be completed in the first quarter of 2024. On completion and submission of the EIA, explains the company will initiate work on the environmental permit process. Anticipates that the definitive feasibility study will begin in mid-2024.

----------

Sabien Technology Group PLC - London-based company focused on green technologies such as plastic-to-oil recycling and CO2 mitigation for commercial and residential boilers - Reviews the value of its investment in Proton Technologies Canada Inc, following the proposed investment in and restructuring of Proton. Concludes that the value of the stake, which is GBP100,000, may require a material impairment provision for the financial year to June 30. Says the level of provision will require agreement with the company's auditors as part of the current audit process.

----------

Eqtec PLC - thermochemical conversion technology and engineering company - Says Eqtec France SAS have completed a technical and commercial feasibility toward deployment of Eqtec solutions at the site of the former Gardanne power station. Completion of the feasibility represents a critical step toward commencement of development and design work on what is expected to be a waste-to-renewable natural gas facility enabled by Eqtec's advanced syngas technology. Expects initial front-end engineering design work to commence in the coming weeks, for which it expects to bill around EUR250,000 for engineering services. Anticipates that it would lead full, front-end engineering design work, estimated to be worth at least EUR750,000 in fees, with the majority to be invoiced over the first half of 2024.

----------

Driver Group PLC - Lancashire, England-based professional services consultancy to construction and engineering industries - Announces a trading update for the year ending September 30. Notes, as indicated in June, the start of the second half was slower than expected. Adds the third quarter experienced reductions in the levels of activity, with an improvement seen in the fourth quarter and a number of significant commissions secured in this period which will benefit the financial year. Expects underlying pretax profit in the financial year compared to a pretax loss of GBP1.0m in the year prior. Also expects to report an improvement in the September 2023 year end cash position from GBP5.3 million in March. Progress has been made on cost reductions including the closure of overseas offices, reduction of existing office lease costs and adjustments to headcount in several locations.

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces the completion of dosing of healthy volunteers in the first two cohorts in the Phase I Protect trial of its virus-like particle-based peanut allergy vaccine candidate. Explains dosing of the subsequent cohorts will begin now that the approval from the external safety review committee has been received. Further, says the safety review committee has approved the commencement of subcutaneous dose escalation in peanut allergic subjects, marking the start of the early proof of concept phase of the Protect trial. This stage of the trial is expected to begin imminently with the full results expected in 2024.

----------

DWF Group PLC - Manchester, England-based legal business with operations in North America - Announces that all of the conditions to the acquisition by Inflexion Private Equity Partners relating to anti-trust and regulatory approvals have been received. Explains the deal remains subject to certain other conditions including the court sanctioning the scheme at the sanction hearing. Subject to satisfaction of these conditions, the scheme is expected to become effective on October 3. Confirms that the sanction hearing will go ahead as scheduled on September 29.

----------

CleanTech Lithium PLC - Chile-focused lithium exploration and development company - Announces results of a recently completed scoping study for the Francisco Basin project. Says these confirm the project's outstanding economics, potential for future resource expansion and strong ESG credentials. Notes this supports the potential for Francisco Basin to become a major supplier of battery grade lithium to European and US markets based on sustainable direct lithium extraction technology. Forecasts a production period of 12 years based on annual production of 20,000 tonnes given Indicated resources. Calculates accumulated net cash flows of USD2.5 billion to be generated over the production period with low operating cost of USD3,641 per tonne of lithium carbonate.

----------

HealthBeacon PLC - Dublin-based devices and software developer for managing critical and chronic medications -

Reports progress with the roll-out of its technology across key channels. However, the scale and complexity of implementations, and the contracting and planning phases of new launches, are running up to 9 months longer than previously estimated. Cautions annual recurring revenue guidance for December 2023 is around EUR3.2 million versus previous estimates of mid-teens by the end of 2023. Revises ARR guidance to approximately EUR17 million by the end of the fourth quarter. To accelerate its path to profitability and improve cash management company plans reduce monthly cash burn to around EUR0.7 million by the end of 2023 and is currently expected to result in cash break even being achieved by the second quarter 2025. To achieve cash break even and scale at the pace now expected, the company has a gross funding requirement of approximately EUR11 million over the next 18-24 months. Therefore, initiates review of funding options to provide the required resources to deliver the forecasted growth into 2024.

Further, says Chief Executive and Co-Founder Jim Joyce is to step down from his role with immediate effect. Joyce will remain as an adviser to the board, and a non-executive director. Rebecca Shanahan, an independent non-executive director, will assume the role of chief executive on an interim basis.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more
29 Sep 2016 11:55

DIRECTOR DEALINGS: Allergy Therapeutics Chairman Lifts Stake

Read more
28 Sep 2016 10:41

DIRECTOR DEALINGS: Allergy Therapeutics Finance Boss Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.